Hu, 2020, Characteristics of SARS-CoV-2 and COVID-19, Nat. Rev. Microbiol.
Krammer, 2020, SARS-CoV-2 vaccines in development, Nature, 586, 516, 10.1038/s41586-020-2798-3
Maurya, 2020, Therapeutic development and drugs for the treatment of COVID-19, 109
Zhu, 2020, A Novel Coronavirus from patients with Pneumonia in China, 2019, N. Engl. J. Med., 382, 727, 10.1056/NEJMoa2001017
Macpherson, 2008, The immune geography of IgA induction and function, Mucosal. Immunol., 1, 11, 10.1038/mi.2007.6
Chen, 2020, Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA, Nat. Rev. Immunol., 20, 427, 10.1038/s41577-019-0261-1
Grzelak, 2020, A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations, Sci. Transl. Med., 12, eabc3103, 10.1126/scitranslmed.abc3103
Lescure, 2020, Clinical and virological data of the first cases of COVID-19 in Europe: a case series, Lancet Infect. Dis., 20, 697, 10.1016/S1473-3099(20)30200-0
Marklund, 2020, Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders, PLoS One, 15, 10.1371/journal.pone.0241104
Kowitdamrong, 2020, Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019, PLoS One, 15, 10.1371/journal.pone.0240502
Yazdanpanah, 2020, Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients, J. Med. Virol., jmv.26601
Cervia, 2021, Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19, J. Allergy Clin. Immunol., 147, 545, 10.1016/j.jaci.2020.10.040
Lou, 2020, Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset, Eur. Respir. J., 56, 10.1183/13993003.00763-2020
Isho, 2020, Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients, Sci. Immunol., 5, 10.1126/sciimmunol.abe5511
Chen, 2020, Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production, Cell, 10.1016/j.cell.2020.10.051
Wajnberg, 2020, Robust neutralizing antibodies to SARS-CoV-2 infection persist for months, Science, 370, 1227, 10.1126/science.abd7728
Gallais, 2020, Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion, Infect. Dis. (except HIV/AIDS)